Marketing Pharmaceuticals 2016

Discuss the complexity of marketing and how to promote pharmaceuticals, biologics, and medical devices in an effective yet compliant manner in an evolving environment.

戻る Agenda

Session 1: Ad-Promo Litigation: Amarin and Beyond

Session Chair(s)

Doug H. Hallward-Driemeier

Partner

Ropes and Gray, LLP, United States

Recent litigation, such as the Amarin and Pacira cases, raise far reaching new issues about the regulatory policies for the advertising and promotion of prescription products. Is a paradigm shift coming? How will the FDA and Congress address these issues? Is still more litigation on the horizon? What should individual companies do right now? This session will provide a brief background on these cases, but focus on the policy and day-to-day practical implications of this litigation.

Speaker(s)

Panelists

Jeff Handwerker

Arnold & Porter, LLC, United States

Partner

Michael Listgarten

Genentech, Inc., United States

Senior Associate General Counsel

John Fleder

Hyman, Phelps & McNamara, United States

Director